Rapid drug development
with clear audit trail
with GxP guidelines
Finding the right prescription for clinical data access
Bayer Pharmaceuticals focuses on researching, developing and marketing specialty-focused, innovative medicines that provide clear clinical benefit and value, primarily in the therapeutic areas of cardiology, oncology, gynecology, hematology and ophthalmology.
To make it faster and easier for researchers to analyze drug development data, the company deployed a microservices-based architecture for its data platform. Having clean, verified traceable clinical data saves development time, accelerates the process of determining proper dosage and drug interactions, and leaves a clear audit trail as per FDA GxP guidelines.